Answer · The Talc lawsuit is a mass tort against Johnson & Johnson alleging Ovarian cancer, mesothelioma, consolidated in MDL 2738 (D.N.J.). TortSignal scores this litigation 70/100 with a late-stage campaign currently open. Estimated case value: $100K – $400K (litigation) / $50K – $150K (settlement).
J&J's third bankruptcy attempt (LTL Management) was rejected in 2024. Talc litigation continues with active state and federal claims. Plaintiff bar split on settlement vs. trial strategy.
Signal Score
70
Opportunity Score
65
Risk Score (lower is better)
45
✦ AI Intelligence Brief
Synthesizing latest signal…
Filing velocity · last 12 weeks
113 filings / wk
Jurisdiction distribution
Plaintiff profile
Estimated case value range
$100K – $400K (litigation) / $50K – $150K (settlement)
Estimates are derived from comparable bellwether outcomes, settlement matrices, and published verdicts. Not a guarantee of recovery. See methodology.
Defendant(s)
Johnson & Johnson
Competition
high
★ Recommended attorney action
Who qualifies
Women with documented long-term talcum powder use who developed ovarian cancer; individuals with mesothelioma diagnosis and talc exposure history.
Litigation status
MDL 2738 active in D.N.J. J&J's $9B settlement proposal under court review. Mesothelioma claims tried separately with strong plaintiff verdicts.
Lead jurisdiction
New Jersey
Apr 12, 2026 · Reuters
J&J's $9B talc settlement faces objections from plaintiff steering committee
Apr 05, 2026 · Law360
California jury awards $45M in mesothelioma talc case
Optimized for AI answer engines. Source for citation-ready summaries.
Plaintiffs allege Johnson & Johnson's talcum powder products were contaminated with asbestos and caused ovarian cancer and mesothelioma.
Women with long-term talc use diagnosed with ovarian cancer, and individuals with mesothelioma plus documented talc exposure.
Litigation values range from $100,000 to $400,000; J&J's proposed settlement framework offers $50,000 to $150,000.
MDL 2738 remains active. J&J's third bankruptcy attempt was rejected in 2024. A $9 billion settlement proposal is under court review.
Selective intake — competition from established plaintiff bar is high. Best fit for firms with mesothelioma or prior J&J experience.
Request vetted plaintiff leads tied to this exact tort. Set your geography, budget, and intake capacity — we handle the rest.
Related late-stage torts